Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 8Neoplasms 2NSCLC 2Colonic Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rectal Neoplasms 1Osteosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bone Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Ibandronic Acid 5Zoledronic Acid 3Denosumab 3pembrolizumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Nivolumab 2Methods 2Interviews as Topic 2Injections 2Curettage 2selinexor 1saracatinib 1ridaforolimus 1radium Ra 223 dichloride 1pegfilgrastim 1olaparib 1montanide ISA 51 1lentiviral minigene vaccine of COVID-19 coronavirus 1endostar protein 1cc-486 1angiotensin I (1-7) 1Vincristine 1Transplantation, Homologous 1Transplantation, Autologous 1Transcranial Direct Current Stimulation 1Trabectedin 1Tomography, Spiral Computed 1TES 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bone Neoplasms × HMPL-013 × Clear all
NCT06202599 2024-01-17

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Peking University People's Hospital

Completed
124 enrolled
Sarcoma

Bone Neoplasms, Neoplasms, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡